Harvard Bioscience Announces Retirement of CEO and Appointment of Interim CEO

Harvard Bioscience Announces Retirement of CEO and Appointment of Interim CEO

HOLLISTON, Mass., May 15, 2013 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc.
(Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range
of tools to advance life science research and regenerative medicine, today
announced that its Board of Directors has appointed David Green, the Company's
President and member of the Board since 1996, as interim Chief Executive
Officer following the retirement and resignation of Chane Graziano as Chief
Executive Officer and a Director of the Company.

Mr. Graziano commented, "I would like to thank all of the Harvard Bioscience
employees worldwide for their commitment and service to the Company over the
past 17 years. We have accomplished a great deal together. I have chosen to
resign today for personal reasons.We are well on our way in the process of
separating Harvard Apparatus Regenerative Technology from Harvard Bioscience
which will unlock significant shareholder value as HART achieves its
milestones, and HBIO once again becomes active in acquiring complementary
product lines or companies.At 74 years of age, 17 years as CEO of HBIO, and
49 years in the industry, it is the right time for me to retire."

The Board of Directors will immediately commence a search to hire a new Chief
Executive Officer.

About Harvard Bioscience

Harvard Bioscience ("HBIO") is a global developer, manufacturer and marketer
of a broad range of specialized products, primarily apparatus and scientific
instruments, used to advance life science research and regenerative medicine.
Our products are sold to thousands of researchers in over 100 countries
primarily through our 850 page catalog (and various other specialty catalogs),
our website, through distributors, including GE Healthcare, Thermo Fisher
Scientific and VWR, and via our field sales organization. HBIO has sales and
manufacturing operations in the United States, the United Kingdom, Germany,
Sweden and Spain with additional facilities in France and Canada. For more
information, please visit www.harvardbioscience.com.

For investor inquiries, please call (508) 893-8066. Press releases may be
found on our web site, http://www.harvardbioscience.com.

The Harvard Bioscience, Inc. logo is available at

CONTACT: David Green
         President and Interim CEO
         Tel: 508 893 8999
         Fax: 508 892 6135
         Tom McNaughton

Harvard Bioscience, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.